Patents by Inventor Steven A. Middleton

Steven A. Middleton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
    Patent number: 8778956
    Abstract: The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.
    Type: Grant
    Filed: December 3, 2008
    Date of Patent: July 15, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kathleen Battista, Gilles Bignan, Peter J. Connolly, Allen B. Reitz, Tina Morgan Ross, Malcolm Scott, Steven A. Middleton, Michael Orsini
  • Substituted pyrimidinyl oxime kinase inhibitors
    Patent number: 8367825
    Abstract: The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: February 5, 2013
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Xu Guozhang, Lily Lee, Terry V. Hughes, Steven K. Wetter, Peter J. Connolly, Marta C. Abad, Stuart L. Emanuel, Prabha S. Kamachi, Steven A. Middleton, Kathleen A. Battista, Gilles C. Bignan
  • Bicyclic pyrimidine kinase inhibitors
    Patent number: 8314234
    Abstract: The present invention is directed to novel bicyclic pyrimidine compounds of Formula (I) or a form or composition thereof and the use thereof as inhibitors of ATP-protein kinase interactions.
    Type: Grant
    Filed: September 20, 2007
    Date of Patent: November 20, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Peter J. Connolly, Stuart Emanuel, Ronghui Lin, Yanhua Lu, Steven A. Middleton
  • 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives
    Patent number: 8299082
    Abstract: 1,2,4-Triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I), pharmaceutically acceptable salts thereof, processes for the manufacture of 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives and pharmaceutical compositions containing 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives are disclosed: The 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I) possess cell cycle inhibitory activity and are accordingly useful for their anti cell proliferation (such as anti cancer) activity.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: October 30, 2012
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Shenlin Huang, Ronghui Lin, Peter J. Connolly, Stuart L. Emanuel, Steven A. Middleton, Robert H. Gruninger, Steven K. Wetter
  • Substituted Pyrimidinyl Oxime Kinase Inhibitors
    Publication number: 20120157412
    Abstract: The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Application
    Filed: February 28, 2012
    Publication date: June 21, 2012
    Inventors: Kathleen A. Battista, Gilles C. Bignan, Guozhang Xu, Lily Lee, Terry V. Hughes, Steven K. Wetter, Peter J. Connolly, Marta C. Abad, Stuart L. Emanuel, Prabha S. Karnachi, Steven A. Middleton
  • Substituted pyrimidinyl oxime kinase inhibitors
    Patent number: 8153791
    Abstract: The present invention is directed to substituted pyrimidine compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
    Type: Grant
    Filed: December 12, 2006
    Date of Patent: April 10, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Guozhang Xu, Lily Lee, Terry V. Hughes, Steven K. Wetter, Peter J. Connolly, Marta C. Abad, Stuart L. Emanuel, Prabha S. Karnachi, Steven A. Middleton, Kathleen A. Battista, Gilles C. Bignan
  • 1,2,4-TRIAZOLYLAMINOARYL (HETEROARYL) SULFONAMIDE DERIVATIVES
    Publication number: 20110077249
    Abstract: 1,2,4-Triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I), pharmaceutically acceptable salts thereof, processes for the manufacture of 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives and pharmaceutical compositions containing 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives are disclosed: The 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I) possess cell cycle inhibitory activity and are accordingly useful for their anti cell proliferation (such as anti cancer) activity.
    Type: Application
    Filed: September 29, 2010
    Publication date: March 31, 2011
    Applicant: Janssen Pharmaceutica N.V.
    Inventors: Shenlin Huang, Ronghui Lin, Peter J. Connolly, Stuart L. Emanuel, Steven A. Middleton, Robert H. Gruninger, Steven K. Wetter
  • 1,2,4-Triazolylaminoaryl (heteroaryl) sulfonamide derivatives
    Patent number: 7888380
    Abstract: 1,2,4-Triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I), pharmaceutically acceptable salts thereof, processes for the manufacture of 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives and pharmaceutical compositions containing 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives are disclosed: The 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I) possess cell cycle inhibitory activity and are accordingly useful for their anti cell proliferation (such as anti cancer) activity.
    Type: Grant
    Filed: October 6, 2005
    Date of Patent: February 15, 2011
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Shenlin Huang, Ronghui Lin, Peter J. Connolly, Stuart L. Emanuel, Steven A. Middleton, Robert H. Gruninger, Steven K. Wetter
  • Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
    Patent number: 7855205
    Abstract: The present invention provides pyrimidinyl substituted fused-pyrrolyl compounds of Formula (I) and pharmaceutical compositions comprising the compounds and methods of synthesis and use thereof. The compounds are kinase inhibitors useful in treating or ameliorating a kinase mediated, angiogenesis-mediated or hyperproliferative disorder. The invention thus also provides a therapeutic or prophylactic method of use for the compounds and/or pharmaceutical compositions to treat such disorders.
    Type: Grant
    Filed: October 28, 2005
    Date of Patent: December 21, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Shenlin Huang, Ronghua Li, Peter J. Connolly, Stuart L. Emanuel, Steven A. Middleton
  • Thiazolopyridine kinase inhibitors
    Patent number: 7659284
    Abstract: The present invention is directed to novel thiazolopyridines, pharmaceutical compositions thereof, and the use thereof as inhibitors of ATP-protein kinase interactions.
    Type: Grant
    Filed: September 15, 2005
    Date of Patent: February 9, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Peter J. Connolly, Sigmond G. Johnson, Niranjan B. Pandey, Steven A. Middleton
  • 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators
    Patent number: 7655670
    Abstract: The present invention is directed to novel 3-spirocyclic indolyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the ORL-1 receptor.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: February 2, 2010
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Kathleen A. Battista, Gilles C. Bignan, Peter J. Connolly, Jessica J. Liu, Steven A. Middleton, Michael J. Orsini
  • Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
    Patent number: 7605154
    Abstract: The present invention is directed to novel thiazolopyrimidine compounds of Formula (I) or a form or composition thereof and the use thereof as inhibitors of ATP-protein kinase interactions.
    Type: Grant
    Filed: August 2, 2006
    Date of Patent: October 20, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Eva Binnun, Peter J. Connolly, Sigmond G. Johnson, Ronghui Lin, Steven A. Middleton, Sandra J. Moreno-Mazza, Niranjan B. Pandey, Steven K. Wetter
  • Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
    Patent number: 7582649
    Abstract: The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.
    Type: Grant
    Filed: October 4, 2005
    Date of Patent: September 1, 2009
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Kathleen Battista, Gilles Bignan, Peter J. Connolly, Allen B. Reitz, Tina Morgan Ross, Malcolm Scott, Steven A. Middleton, Michael Orsini
  • 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
    Patent number: 7541367
    Abstract: The present invention is directed to novel 3-benzoimidazolyl-pyrazolopyridine compounds of formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of serine-threonine protein kinases and tyrosine protein kinases and interactions thereof.
    Type: Grant
    Filed: May 31, 2006
    Date of Patent: June 2, 2009
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: George Chiu, Peter J. Connolly, Stuart Emanuel, Shenlin Huang, Shengjian Li, Ronghui Lin, Yanhua Lu, Steven A. Middleton
  • HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS
    Publication number: 20090124614
    Abstract: The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, panic, dementia, mania, bipolar disorder, substance abuse, neuropathic pain, acute pain, chronic pain, migraine, asthma, cough, psychosis, schizophrenia, epilepsy, hypertension, obesity, eating disorders, cravings, diabetes, cardiac arrhythmia, irritable bowel syndrome, Crohn's disease, urinary incontinence, adrenal disorders, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, for improved cognition or memory and for mood stabilization.
    Type: Application
    Filed: December 3, 2008
    Publication date: May 14, 2009
    Inventors: Kathleen BATTISTA, Gilles BIGNAN, Peter J. CONNOLLY, Allen B. REITZ, Tina Morgan ROSS, Malcolm SCOTT, Steven A. MIDDLETON, Michael ORSINI
  • Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds
    Patent number: 7517885
    Abstract: The present invention relates to substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: April 14, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: George Chiu, Peter J. Connolly, Jessica J. Liu, Steven A. Middleton, Virginia L. Pulito, Shengjian Li
  • BICYCLIC PYRIMIDINE KINASE INHIBITORS
    Publication number: 20090076037
    Abstract: The present invention is directed to novel bicyclic pyrimidine compounds of Formula (I) or a form or composition thereof and the use thereof as inhibitors of ATP-protein kinase interactions.
    Type: Application
    Filed: September 20, 2007
    Publication date: March 19, 2009
    Inventors: Peter J. Connolly, Stuart Emanuel, Ronghui Lin, Yanhua Lu, Steven A. Middleton
  • 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
    Publication number: 20090048249
    Abstract: The present invention is directed to novel 3-benzoimidazolyl-pyrazolopyridine compounds of formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of serine-threonine protein kinases and tyrosine protein kinases and interactions thereof.
    Type: Application
    Filed: May 31, 2006
    Publication date: February 19, 2009
    Inventors: George Chiu, Peter J. Connolly, Stuart Emanuel, Shenlin Huang, Shengjian Li, Ronghui Lin, Yanhua Lu, Steven A. Middleton
  • Piperazinyl substituted cyclohexane-1,4-diamines
    Patent number: 7482348
    Abstract: The present invention relates to piperazine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: January 27, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: George Chiu, Shengjian Li, Peter J. Connolly, Virginia L. Pulito, Jingchun Liu, Steven A. Middleton
  • Piperidinyl substituted cyclohexane-1,4-diamines
    Patent number: 7470711
    Abstract: The present invention relates to piperidine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as ?1a/?1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: December 30, 2008
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: George Chiu, Shengjian Li, Peter J. Connolly, Virginia L. Pulito, Jingchun Liu, Steven A. Middleton